Shares of ARMO BioSciences (NASDAQ:ARMO) have been given an average broker rating score of 1.50 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and three have issued a strong buy recommendation on the company.
Analysts have set a twelve-month consensus price objective of $63.25 for the company and are predicting that the company will post ($0.45) EPS for the current quarter, according to Zacks. Zacks has also assigned ARMO BioSciences an industry rank of 185 out of 265 based on the ratings given to its competitors.
A number of equities research analysts have weighed in on the company. Jefferies Group assumed coverage on ARMO BioSciences in a research note on Tuesday, February 20th. They issued a “buy” rating and a $61.00 price objective for the company. BMO Capital Markets started coverage on ARMO BioSciences in a research note on Tuesday, February 20th. They set an “outperform” rating and a $75.00 price target for the company. Leerink Swann restated a “market perform” rating on shares of ARMO BioSciences in a research note on Tuesday, February 20th. Finally, Robert W. Baird started coverage on ARMO BioSciences in a research note on Tuesday, February 20th. They set an “outperform” rating and a $67.00 price target for the company.
TRADEMARK VIOLATION NOTICE: This article was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3303323/analysts-set-63-25-price-target-for-armo-biosciences-armo.html.
About ARMO BioSciences
ARMO Biosciences, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company’s platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects that induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in cancer patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ARMO BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARMO BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.